Want to see DE:RDC full AI Analyst Report?
RDC Stock Chart & Stats
€50.50
€4.70(3.90%)
At close: 4:00 PM EST
€50.50
€4.70(3.90%)
Day’s Range― - ―
52-Week Range€30.20 - €114.00
Previous CloseN/A
Volume73.26K
Average Volume (3M)132.76K
Market Cap
€1.33B
Enterprise Value€1.57B
Total Cash (Recent Filing)€135.00M
Total Debt (Recent Filing)€354.80M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Jul 29, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding20,578,390
10 Day Avg. Volume128,637
30 Day Avg. Volume132,758
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.85
Price to Sales (P/S)0.45
P/FCF Ratio-23.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€76.71Price Target Upside51.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€3.40B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent multi-year top-line expansion (TTM sales materially higher) demonstrates durable demand for Redcare’s e-pharmacy offerings and scale gains across markets. Sustained revenue growth supports investment in fulfillment, marketing efficiency and long-term margin improvement as scale benefits accrue.
Platform Business Model & Addressable MarketA digital, multi-market e-pharmacy model with centralized fulfillment and digital customer acquisition creates structural advantages: lower incremental distribution cost, repeat purchase potential from OTC/beauty categories, and expanding Rx addressable market as e-prescription adoption reduces friction for online dispensing.
Manageable LeverageA debt-to-equity around 0.79 and improving leverage reduce refinancing and solvency risk over the medium term. This balance-sheet posture provides capacity to fund operational scaling or strategic investments without immediate distress, assuming continued progress toward cash conversion.
Bears Say
Persistent LossesOngoing operating losses mean the business has not yet converted scale into sustainable bottom-line profits. Persistent negative net income weakens retained earnings and limits internal funding for growth, increasing reliance on external financing until consistent profitability is achieved.
Weak Cash Conversion / Deeply Negative FCFDeeply negative trailing free cash flow signals that growth and working-capital demands are outstripping cash generation. This raises structural funding risk: continued negative FCF forces dependence on capital markets or debt, which can constrain strategic options and raise financing costs if markets tighten.
Regulatory / Reimbursement ComplexityOperating across multiple European reimbursement systems and evolving e-prescription rules introduces durable regulatory and payor complexity. Differences in reimbursement mechanics can limit uniform margin capture, slow rollouts of Rx services, and create execution risk when expanding markets or integrating prescription flows.
RDC FAQ
What was Redcare Pharmacy’s price range in the past 12 months?
Redcare Pharmacy lowest stock price was €30.20 and its highest was €114.00 in the past 12 months.
What is Redcare Pharmacy’s market cap?
Redcare Pharmacy’s market cap is €1.33B.
When is Redcare Pharmacy’s upcoming earnings report date?
Redcare Pharmacy’s upcoming earnings report date is Jul 29, 2026 which is in 29 days.
How were Redcare Pharmacy’s earnings last quarter?
Redcare Pharmacy released its earnings results on May 06, 2026. The company reported -€0.503 earnings per share for the quarter, missing the consensus estimate of -€0.458 by -€0.045.
Is Redcare Pharmacy overvalued?
According to Wall Street analysts Redcare Pharmacy’s price is currently Undervalued.
Does Redcare Pharmacy pay dividends?
Redcare Pharmacy does not currently pay dividends.
What is Redcare Pharmacy’s EPS estimate?
Redcare Pharmacy’s EPS estimate is -0.27.
How many shares outstanding does Redcare Pharmacy have?
Redcare Pharmacy has 20,578,390 shares outstanding.
What happened to Redcare Pharmacy’s price movement after its last earnings report?
Redcare Pharmacy reported an EPS of -€0.503 in its last earnings report, missing expectations of -€0.458. Following the earnings report the stock price went down -5.391%.
Which hedge fund is a major shareholder of Redcare Pharmacy?
Currently, no hedge funds are holding shares in DE:RDC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Redcare Pharmacy Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€76.71 (51.91% Upside)
€76.71 (51.91% Upside)
Insider Transactions
Sold Shares
Worth €168.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.98%
12-Months-Change
Fundamentals
Return on Equity
-7.79%
Trailing 12-Months
Asset Growth
15.34%
Trailing 12-Months
Company Description
Redcare Pharmacy
Redcare Pharmacy N.V. manages and runs a network of digital pharmacies across Germany, Austria, Switzerland, France, Belgium, Italy, and the Netherlands. The company offers a comprehensive selection of healthcare products, including prescription medications, over-the-counter drugs, pharmacy-related beauty and personal care items, and nutritional supplements. Established in 2001, the firm, initially known as Shop Apotheke Europe N.V., officially rebranded to Redcare Pharmacy N.V. in June 2023. Its operational headquarters are situated in Sevenum, the Netherlands.
RDC Stock 12 Month Forecast
Average Price Target
€76.71
▲(51.91% Upside)
Technical Analysis
Options Prices
Currently, No data available
---